Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sudapyridine (WX-081) for Rifampicin-Resistant Pulmonary Tuberculosis
NCT05824871Phase 3Recruiting
- Sponsor
- Shanghai Jiatan Pharmatech
- Start
- Sep 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sudapyridine in Tuberculosis (TB), sponsored by Shanghai Jiatan Pharmatech. Started Sep 2022; status: recruiting.
02
Drugs
sudapyridine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT05824871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05824871.